Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Study PTM-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12
week open-label extension to examine the immunomodulatory activity of PTM-001 in participants
with Hidradenitis Suppurativa (HS). Participants will be randomized to receive PTM-001 (400
mg) or matching placebo every day for 12 weeks after which all participants will receive
open-label PTM-001 400 mg daily for an additional 12 weeks. Randomization will be stratified
by Hurley Stage.